ATLANTA - New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found that the biologic B-cell inhibitor belimumab was associated with a ...
Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Patients with non-renal systemic lupus erythematosus who receive belimumab demonstrate a lower ...
Belimumab may reduce the risk for all-cause mortality compared with oral immunosuppressants among patients with nonrenal systemic lupus erythematosus. Belimumab use is associated with a reduced risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback